Bausch Health Cos PE Ratio 2012-2025 | BHC
Current and historical p/e ratio for Bausch Health Cos (BHC) from 2012 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Bausch Health Cos PE ratio as of April 14, 2026 is 1.50.
| Bausch Health Cos PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-04-15 | 5.74 | 13.67 | |
| 2025-12-31 | 6.95 | $0.42 | 16.55 |
| 2025-09-30 | 6.45 | $0.96 | 6.72 |
| 2025-06-30 | 6.66 | $0.25 | 26.64 |
| 2025-03-31 | 6.47 | $-0.12 | 0.00 |
| 2024-12-31 | 8.06 | $-0.13 | 0.00 |
| 2024-09-30 | 8.16 | $-0.48 | 0.00 |
| 2024-06-30 | 6.97 | $-1.28 | 0.00 |
| 2024-03-31 | 10.61 | $-1.24 | 0.00 |
| 2023-12-31 | 8.02 | $-1.62 | 0.00 |
| 2023-09-30 | 8.22 | $-2.64 | 0.00 |
| 2023-06-30 | 8.00 | $-0.51 | 0.00 |
| 2023-03-31 | 8.10 | $-0.98 | 0.00 |
| 2022-12-31 | 6.28 | $-0.62 | 0.00 |
| 2022-09-30 | 6.89 | $0.72 | 9.57 |
| 2022-06-30 | 8.36 | $0.14 | 59.71 |
| 2022-03-31 | 22.85 | $-1.12 | 0.00 |
| 2021-12-31 | 27.61 | $-2.64 | 0.00 |
| 2021-09-30 | 27.85 | $-3.28 | 0.00 |
| 2021-06-30 | 29.32 | $-3.60 | 0.00 |
| 2021-03-31 | 31.74 | $-2.86 | 0.00 |
| 2020-12-31 | 20.80 | $-1.58 | 0.00 |
| 2020-09-30 | 15.54 | $-5.45 | 0.00 |
| 2020-06-30 | 18.29 | $-5.79 | 0.00 |
| 2020-03-31 | 15.50 | $-5.36 | 0.00 |
| 2019-12-31 | 29.92 | $-5.08 | 0.00 |
| 2019-09-30 | 21.85 | $-1.74 | 0.00 |
| 2019-06-30 | 25.22 | $-2.60 | 0.00 |
| 2019-03-31 | 24.70 | $-4.60 | 0.00 |
| 2018-12-31 | 18.47 | $-11.81 | 0.00 |
| 2018-09-30 | 25.67 | $-9.39 | 0.00 |
| 2018-06-30 | 23.24 | $-4.70 | 0.00 |
| 2018-03-31 | 15.92 | $-2.32 | 0.00 |
| 2017-12-31 | 20.78 | $6.83 | 3.04 |
| 2017-09-30 | 14.33 | $3.88 | 3.69 |
| 2017-06-30 | 17.30 | $-3.30 | 0.00 |
| 2017-03-31 | 11.03 | $-4.07 | 0.00 |
| 2016-12-31 | 14.52 | $-6.94 | 0.00 |
| 2016-09-30 | 24.55 | $-6.57 | 0.00 |
| 2016-06-30 | 20.14 | $-2.94 | 0.00 |
| 2016-03-31 | 26.30 | $-2.21 | 0.00 |
| 2015-12-31 | 101.65 | $-0.85 | 0.00 |
| 2015-09-30 | 178.38 | $1.74 | 102.75 |
| 2015-06-30 | 222.15 | $2.41 | 92.33 |
| 2015-03-31 | 198.62 | $2.93 | 67.79 |
| 2014-12-31 | 143.11 | $2.58 | 55.47 |
| 2014-09-30 | 131.20 | $1.39 | 94.39 |
| 2014-06-30 | 126.12 | $-2.34 | 0.00 |
| 2014-03-31 | 131.83 | $-2.68 | 0.00 |
| 2013-12-31 | 117.40 | $-2.70 | 0.00 |
| 2013-09-30 | 104.33 | $-3.27 | 0.00 |
| 2013-06-30 | 86.08 | $-0.33 | 0.00 |
| 2013-03-31 | 75.02 | $-0.43 | 0.00 |
| 2012-12-31 | 59.77 | $-0.38 | 0.00 |
| 2012-09-30 | 55.27 | $0.08 | 690.88 |
| 2012-06-30 | 44.79 | $0.19 | 235.74 |
| 2012-03-31 | 53.69 | $0.43 | 124.86 |
| 2011-12-31 | 46.69 | $0.49 | 95.29 |
| 2011-09-30 | 37.12 | $0.34 | 109.18 |
| 2011-06-30 | 51.96 | $-1.06 | 0.00 |
| 2011-03-31 | 49.81 | $-1.02 | 0.00 |
| 2010-12-31 | 28.29 | $-1.06 | 0.00 |
| 2010-09-30 | 24.08 | $-0.62 | 0.00 |
| 2010-06-30 | 18.42 | $0.90 | 20.47 |
| 2010-03-31 | 15.96 | $0.84 | 18.99 |
| 2009-12-31 | 13.20 | $1.11 | 11.90 |
| 2009-09-30 | 14.50 | $1.41 | 10.29 |
| 2009-06-30 | 12.55 | $1.47 | 8.54 |
| 2009-03-31 | 10.14 | $1.16 | 8.74 |
| 2008-12-31 | 8.45 | $1.26 | 6.71 |
| 2008-09-30 | 8.38 | $0.30 | 27.92 |
| 2008-06-30 | 7.98 | $0.40 | 19.94 |
| 2008-03-31 | 8.55 | $0.98 | 8.72 |
| 2007-12-31 | 10.46 | $1.21 | 8.65 |
| 2007-09-30 | 13.21 | $2.13 | 6.20 |
| 2007-06-30 | 18.89 | $1.37 | 13.79 |
| 2007-03-31 | 16.01 | $1.45 | 11.04 |
| 2006-12-31 | 14.88 | $1.27 | 11.72 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.086B | $10.266B |
| Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |